Back to Search Start Over

CGCG clinical practice guidelines for the management of adult diffuse gliomas

Authors :
Lianwang Li
Hongmin Bai
Yu Wang
Kun Yao
Gan You
Tao Jiang
Yiwu Dai
Shouwei Li
Jinquan Cai
Yuan Yang
Weimin Wang
Guanzhang Li
Xuejun Li
Shaowu Li
Zhixiong Liu
Hongjun Wang
Yinyan Wang
Zvi Ram
Wenbin Li
Huimin Hu
Qing Mao
Sheng-Qing Lv
Baoshi Chen
Wenbin Ma
Yiming Li
Zhaoshi Bao
Yanwei Liu
Anhua Wu
Yu-Qing Liu
Ruichao Chai
Damdindorj Boldbaatar
Jing Chen
Chunsheng Kang
Xing Liu
Xuejun Yang
Do-Hyun Nam
Guozheng Xu
Zhixiong Lin
Lingchao Chen
Shengyu Fang
Xiaoguang Qiu
Xinting Wei
Jiguang Wang
Xiaodong Ma
Xing Fan
Liang Wang
Jun Dong
Zhiliang Wang
Wei Yan
Ke Sai
Wai Sang Poon
Xia Shan
Zhiwen Zhang
Qixue Wang
Xianzhi Liu
Guilin Li
Chuanbao Zhang
Yu Yao
Pei Yang
Zheng Zhao
Lei Han
Ying Mao
Ling Chen
Zheng Wang
Shuai Liu
Wei Zhang
Yongzhi Wang
Chuanlu Jiang
Yongping You
Source :
Cancer Letters. 375:263-273
Publication Year :
2016
Publisher :
Elsevier BV, 2016.

Abstract

The Chinese Glioma Cooperative Group (CGCG) Guideline Panel for adult diffuse gliomas provided recommendations for diagnostic and therapeutic procedures. The Panel covered all fields of expertise in neuro-oncology, i.e. neurosurgeons, neurologists, neuropathologists, neuroradiologists, radiation and medical oncologists and clinical trial experts. The task made clearer and more transparent choices about outcomes considered most relevant through searching the references considered most relevant and evaluating their value. The scientific evidence of papers collected from the literature was evaluated and graded based on the Oxford Centre for Evidence-based Medicine Levels of Evidence and recommendations were given accordingly. The recommendations will provide a framework and assurance for the strategy of diagnostic and therapeutic measures to reduce complications from unnecessary treatment and cost. The guideline should serve as an application for all professionals involved in the management of patients with adult diffuse glioma and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in China.

Details

ISSN :
03043835
Volume :
375
Database :
OpenAIRE
Journal :
Cancer Letters
Accession number :
edsair.doi.dedup.....34f9df09814f6f9fc2f6dcc63fdf49fd
Full Text :
https://doi.org/10.1016/j.canlet.2016.01.024